Evidence map›Paper›PMID 38714644›Full record

ArticleNature communications2024

Complete male-to-female sex reversal in XY mice lacking the miR-17~92 cluster.

Alicia Hurtado, Irene Mota-Gómez, Miguel Lao, Francisca M Real, Johanna Jedamzick, Miguel Burgos, Darío G Lupiáñez, Rafael Jiménez, Francisco J Barrionuevo

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. The Heterogeneous Nuclear Ribonucleoprotein K (Animals : an open access journal from MDPI · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alicia Hurtado *Department of Genetics and Institute of Biotechnology, Labs. 127 and A105, Centre for Biomedical Research, University of Granada, Armilla, Granada, Spain.ORCID http://orcid.org/0000-0001-6267-704X
Irene Mota-Gómez *Epigenetics and Sex Development Group, Berlin Institute for Medical Systems Biology, Max-Delbrück Center for Molecular Medicine, Berlin, Germany.ORCID http://orcid.org/0000-0001-8308-8017
Miguel Lao *Department of Genetics and Institute of Biotechnology, Labs. 127 and A105, Centre for Biomedical Research, University of Granada, Armilla, Granada, Spain.ORCID http://orcid.org/0000-0001-6707-6825
Francisca M RealResearch Group Development & Disease, Max Planck Institute for Molecular Genetics, Berlin, Germany.ORCID http://orcid.org/0000-0003-0692-2260
Johanna JedamzickEpigenetics and Sex Development Group, Berlin Institute for Medical Systems Biology, Max-Delbrück Center for Molecular Medicine, Berlin, Germany.
Miguel BurgosDepartment of Genetics and Institute of Biotechnology, Labs. 127 and A105, Centre for Biomedical Research, University of Granada, Armilla, Granada, Spain.ORCID http://orcid.org/0000-0003-4446-9313
Darío G Lupiáñez *Epigenetics and Sex Development Group, Berlin Institute for Medical Systems Biology, Max-Delbrück Center for Molecular Medicine, Berlin, Germany. dario.lupianez@csic.es.ORCID http://orcid.org/0000-0002-3165-036X
Rafael Jiménez *Department of Genetics and Institute of Biotechnology, Labs. 127 and A105, Centre for Biomedical Research, University of Granada, Armilla, Granada, Spain. rjimenez@ugr.es.ORCID http://orcid.org/0000-0003-4103-8219
Francisco J Barrionuevo *Department of Genetics and Institute of Biotechnology, Labs. 127 and A105, Centre for Biomedical Research, University of Granada, Armilla, Granada, Spain. fjbarrio@go.ugr.es.ORCID http://orcid.org/0000-0003-2651-1530

Funding

Consejería de Economía, Innovación, Ciencia y Empleo, Junta de Andalucía (Ministry of Economy, Innovation, Science and Employment, Government of Andalucia) P11-CVI-7291Consejería de Economía, Innovación, Ciencia y Empleo, Junta de Andalucía (Ministry of Economy, Innovation, Science and Employment, Government of Andalucia) P20-00583Deutsche Forschungsgemeinschaft (German Research Foundation) IRTG2403EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) grant no. 101045439, 3D-REVOLUTION
6 · The paper itself

Abstract

Mammalian sex determination is controlled by antagonistic gene cascades operating in embryonic undifferentiated gonads. The expression of the Y-linked gene SRY is sufficient to trigger the testicular pathway, whereas its absence in XX embryos leads to ovarian differentiation. Yet, the potential involvement of non-coding regulation in this process remains unclear. Here we show that the deletion of a single microRNA cluster, miR-17~92, induces complete primary male-to-female sex reversal in XY mice. Sry expression is delayed in XY knockout gonads, which develop as ovaries. Sertoli cell differentiation is reduced, delayed and unable to sustain testicular development. Pre-supporting cells in mutant gonads undergo a transient state of sex ambiguity which is subsequently resolved towards the ovarian fate. The miR-17~92 predicted target genes are upregulated, affecting the fine regulation of gene networks controlling gonad development. Thus, microRNAs emerge as key components for mammalian sex determination, controlling Sry expression timing and Sertoli cell differentiation.

Indexed as

Cell DifferentiationMicroRNAsOvarySertoli CellsSex Determination ProcessesSex-Determining Region Y ProteinTestisAnimalsDisorders of Sex DevelopmentFemaleGene Expression Regulation, DevelopmentalGonadsMaleMiceMice, KnockoutSex DifferentiationMicroRNAsMIRN17-92 microRNA, mouseSex-Determining Region Y ProteinSry protein, mouse

Identifiers

PMID38714644
PMCPMC11076593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.